Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration

摘要

Parkinson’s disease is one of the most common neurological diseases. Pathogenesis of the disease is associated with destruction and death of neurons that produce the neurotransmitter dopamine. The precursor to dopamine, which crosses the protective blood-brain barrier, is the amino acid 3, 4-dihydroxy-L-phenylalanine – levodopa, L-DOPA. The investigational drug is a pharmaceutical composition, containing L-DOPA as an active substance, which is distributed in a polymer matrix based on a biodegradable copolymer of lactic/glycolic acids.